Compare Knopp Biosciences vs Sentinel Oncology
Customers evaluate the quality of Knopp Biosciences's products using the following success metrics.
Overview
Knopp Biosciences is 20 yrs old and is based in United States.
Knopp Biosciences is a drug discovery and development company focused on delivering treatments for unmet medical needs through experience and partnership. The company's clinical and preclinical programs focus on mechanisms of mitochondrial energetics and its lead compound, dexpramipexole, is currently in Phase 3 clinical development for amyotrophic lateral sclerosis. Additional programs include dexpramipexole combination therapy for Parkinson's disease and the discovery of ion channel modulators for pain and epilepsy.
Sentinel Oncology is 19 yrs old and is based in United Kingdom.
Sentinel Oncology is a small molecule drug discovery company focusing on the discovery and development of new chemical entities for the treatment of cancer.
Demo Video
Leadership
Gregory T. Hebrank (Executive Vice President)
Robert G. Boyle (Chief Executive Officer)
Investors
National Institutes of Health, Saturn Partners
Cambridge Enterprise Seed Funds
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Knopp Biosciences has not claimed their profile.
Work for Knopp Biosciences? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Knopp Biosciences?
Claim your profile now.
Information not available because Sentinel Oncology has not claimed their profile.
Work for Sentinel Oncology? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Sentinel Oncology?
Claim your profile now.